ArticleClinical cardiology2014
Adiponectin levels are elevated in patients with pulmonary arterial hypertension.
Article in Clinical cardiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Plasma soluble ST2 levels correlate with disease severity and predict clinical worsening in patients with pulmonary arterial hypertension.Clinical cardiology · 2014Trial
- Adipokines in pulmonary hypertension: angels or demons?Heliyon · 2023Review
- The Glycobiology of Pulmonary Arterial Hypertension.Metabolites · 2022Review
- A systematic review with meta-analysis of biomarkers for detection of pulmonary arterial hypertension.ERJ open research · 2022Review
- Soluble ST2 and mixed venous oxygen saturation for prediction of mortality in patients with pulmonary hypertension.Journal of thoracic disease · 2021Article
- Adipokines and Metabolic Regulators in Human and Experimental Pulmonary Arterial Hypertension.International journal of molecular sciences · 2021Article
- Adipocytokines: Are they the Theory of Everything?Cytokine · 2020Review
- High plasma adiponectin is associated with increased pulmonary blood flow and reduced right ventricular function in patients with pulmonary hypertension.BMC pulmonary medicine · 2020Article
- Visfatin and chemerin levels correspond with inflammation and might reflect the bridge between metabolism, inflammation and fibrosis in patients with systemic sclerosis.Postepy dermatologii i alergologii · 2019Article
- Pulmonary Hypertension and Obesity: Focus on Adiponectin.International journal of molecular sciences · 2019Review
- Relevance of angiopoietin-2 and soluble P-selectin levels in patients with pulmonary arterial hypertension receiving combination therapy with oral treprostinil: a FREEDOM-C2 biomarker substudy.Pulmonary circulation · 2016Article
- Metabolic Dysfunction in Pulmonary Arterial Hypertension.Current hypertension reports · 2015Review
- Is pulmonary hypertension a metabolic disease?American journal of respiratory and critical care medicine · 2014Article
- Do single or sequential measurements of leptin and adiponectin in plasma have prognostic value in pulmonary arterial hypertension?Pulmonary circulationArticle
- Association of plasma adiponectin with pulmonary hypertension, mortality and heart failure in African Americans: Jackson Heart Study.Pulmonary circulationArticle
- Obesity, estrogens and adipose tissue dysfunction - implications for pulmonary arterial hypertension.Pulmonary circulationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn addition to insulin-sensitizing effects, adiponectin influences several mechanisms involved in pulmonary arterial hypertension (PAH) pathobiology. Insulin resistance has been associated with PAH, and elevated adiponectin levels have been described in left heart failure (HF) as a response to the increased metabolic stress. No studies have been performed in right HF or PAH patients. HYPOTHESIS: Compared to healthy controls, PAH patients have a different plasma adipocytokine profile, higher insulin resistance, and higher inflammatory systemic activation.
methodsA case-control study was conducted in PAH patients individually matched for sex, age, and body mass index. We characterized the clinical features, functional status (6-minute walking test), and hemodynamic profile of cases (n=25). We measured insulin resistance (homeostasis model assessment and high-density lipoprotein/triglycerides ratio), inflammatory systemic activation (high-sensitivity C-reactive protein), and plasma adipocytokine profile (adiponectin, leptin, visfatin, and resistin) in cases and controls.
resultsPAH patients had significantly higher adiponectin levels than controls (12.4±6.9 vs 8.1±4.5 µg/mL; P<0.05) and higher high-sensitivity C-reactive protein (2.96±3.2 vs 1.08±1.1; P<0.05). No statistically significant differences were found in plasma levels of leptin, visfatin, and resistin between groups.
conclusionsAdiponectin levels are increased in PAH patients compared to controls. Further studies are needed to study the potential role of adiponectin as a PAH biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.